PT-141
PT-141 (Bremelanotide) is primarily studied and used to treat sexual dysfunction by acting directly on the central nervous system to increase sexual desire. It is FDA-approved for treating acquired, generalized Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women and is studied for treating erectile dysfunction and low libido in men
Key Areas of Study and Application:
- Hypoactive Sexual Desire Disorder (HSDD): Evaluated for treating low sexual desire not caused by medical/mental health conditions, relationship issues, or drugs.
- Erectile Dysfunction (ED): Studied as a treatment for men who fail to respond to PDE5 inhibitors (like Viagra), as PT-141 works through the nervous system, not just blood flow.
- Female Sexual Arousal Disorder: Targeted to help with desire and arousal issues.
- Mechanism of Action: Research focuses on its role as a melanocortin receptor agonist (specifically MC4R), which initiates sexual desire in the brain.
